JW HOLDINGS CORPORATION
Financials
Valuation Metrics
JW HOLDINGS CORPORATION's Market Cap is ₩3216B. At end of 2025 it was ₩2654B. Ranked #629 of 2,421 in KR market (top 26%), #371 of 781 on KOSPI (top 48%), #66 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 29%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 321.57B KRW | KR#629/2,421 Sec#66/231 |
| Revenue | 1.01T KRW | KR#409/2,421 Sec#14/231 |
| Net Income | 156.71B KRW | KR#180/2,421 Sec#11/231 |
| Total Assets | 1.28T KRW | KR#414/2,421 Sec#20/231 |
| Net Assets | 645.69B KRW | KR#416/2,421 Sec#27/231 |
| Employees | 139 | KR#1,384/2,421 Sec#110/231 |
| Value | ||
| P/E | 2.05x | KR#76/2,421 Sec#3/231 |
| P/B | 0.50x | KR#797/2,421 Sec#37/231 |
| PEG | 0.01x | KR#132/2,421 Sec#5/231 |
| P/S | 0.32x | KR#615/2,421 Sec#17/231 |
| EV/EBITDA | 3.06x | KR#87/2,421 Sec#1/231 |
| FCF Yield | 41.76% | KR#111/2,421 Sec#1/231 |
| Profitability | ||
| ROE | 24.27% | KR#108/2,421 Sec#9/231 |
| ROA | 12.29% | KR#180/2,421 Sec#16/231 |
| Op. Margin | 18.82% | KR#184/2,421 Sec#18/231 |
| Revenue Growth | 10.18% | KR#887/2,421 Sec#85/231 |
| Earnings Growth | 161.13% | KR#291/2,421 Sec#17/231 |
| Financial Health | ||
| Debt Ratio | 97.55% | KR#1,536/2,421 Sec#174/231 |
| Total Debt | 335.32B KRW | KR#381/2,421 Sec#19/231 |
| FCF | 134.28B KRW | KR#147/2,421 Sec#7/231 |
| Cash | 75.01B KRW | KR#578/2,421 Sec#29/231 |
| Current Ratio | 0.79x | KR#1,941/2,421 Sec#189/231 |
| Net Debt/EBITDA | 1.37x | KR#773/2,421 Sec#52/231 |
| Dividend | ||
| Div. Yield | 4.97% | KR#282/2,421 Sec#8/231 |
| Div. Growth | 86.96% | KR#157/2,421 Sec#4/231 |
| Performance | ||
| 1Y Return | 29.66% | KR#369/2,421 Sec#22/231 |
| 1M Return | 9.43% | KR#510/2,421 Sec#34/231 |
| From 52W High | -7.84% | KR#51/2,421 Sec#2/231 |
| 1Y MDD | -19.91% | KR#58/2,421 Sec#3/231 |
| Trading | ||
| Volume | 216,614 shares | KR#462/2,421 Sec#28/231 |
| Trading Value | 957.1M KRW | KR#731/2,421 Sec#74/231 |
| Foreign Own. | 3.33% | KR#1,194/2,421 Sec#111/231 |
| Per Share | ||
| EPS | 2,120 KRW | KR#435/2,421 Sec#27/231 |
| BPS | 8,734 KRW | KR#1,075/2,421 Sec#74/231 |
Company Info
Established in 2007 as a holding company through a human spin-off of the investment and overseas business divisions from JW Pharmaceutical, the company changed its name to JW Holdings in 2010. As of the end of the current quarter, it has six subsidiaries, including JW Pharmaceutical, engaged in pharmaceutical manufacturing and sales, R&D, and medical device manufacturing and sales. Through JW Pharmaceutical, the company has entered global Phase 3 trials for the gout treatment URC102 and received clinical Phase 1 approval for the STAT3 targeted anticancer drug JW2286, driving innovative new drug development. JW Holdings is headquartered in Gwacheon, Gyeonggi-do.